Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Bullboard Posts
Comment by jordon3on Jun 03, 2018 10:21am
121 Views
Post# 28116950

RE:RE:RE:RE:RE:RE:RE:Do we have strength in numbers for upcoming vote?

RE:RE:RE:RE:RE:RE:RE:Do we have strength in numbers for upcoming vote?Alltimehigh, that is an excellent post. Shareholders must let PMN understand that they do NOT want this option cash grab at this point and certainly do NOT want a RS ever.    Time to show and tell the goods and  hopefully SELL  PMN before it is diluted into oblivion.    I am with Mitchellb...a RS would be a disaster for shareholders and especially long term shareholders.  This potential RS needs to be put to rest....who would buy any shares or any more shares wondering if most will be taken away with a RS. Management must be let know loud and clear that this is not wanted by shareholders.

Again at this point if PMN  has the goods, why hasn't anyone made a reasonable offer to buy them out.  5-10 billion is nothing to these big pharma companies if Pmn truly has a best in class situation. Something certainly seems off to be sitting at 36 cents at this stage imo.  
Bullboard Posts